David Planchard and Bruce E. Johnson (2018) BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. Archives of Pathology & Laboratory Medicine: July 2018, Vol. 142, No. 7, pp. 796-797.
SPECIAL SECTION—COMMENTARIES ON THE UPDATED MOLECULAR TESTING GUIDELINE FOR LUNG CANCER PATIENTS
David Planchard,
MD, PhD;
Bruce E. Johnson,
MD
From the Department of Medical Oncology, Gustave Roussy, Villejuif, France (Dr Planchard); and the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, (Dr Johnson).
"...based on the high ORR and mPFS with BRAF/MEK inhibition in phase II trials, current data support the recommendation of the association of dabrafenib with trametinib in NSCLC BRAF V600E mutant as an earlier line of treatment as standard of care. Immune checkpoint therapy is an option; however, given the lack of data in this population, clinicians should remain prudent about substituting checkpoint inhibitor therapy for the evidenced-based precision medicine treatment strategies."
No comments:
Post a Comment